Jim Cramer Comments on J&J's Potential Deal With Actelion

Jim Cramer is watching shares of Johnson & Johnson (JNJ) - Get Report  as the company considers buying Swiss drugmaker Actelion, which specializes in blood pressure drugs. Reuters reported that J&J is raising its offer for the company, and Actelion shares closed up 10%. Last week the companies confirmed they were holding talks about a possible deal. Cramer says it's important to see how the deal is structured before determining if it's there's a buy.